£3.4M
Maven Capital Partners co-led the £3.4m round to support the firm in scaling its operations overseas, notably in the US market.
Gi
Gen inCode
Gen inCode provides genetic testing and predictive DNA risk assessment products for healthcare practitioners.
United Kingdom—Founded 2018
£3.4MTotal raised
Gen inCode is a genetic testing business that develops patented DNA risk assessment products for major global disease areas. Its proprietary algorithms provide predictive analysis to help healthcare practitioners personalise treatment pathways.
Categories
Team
MW
Matthew Walls
Chairman and CEO
Matthew brings extensive leadership experience as chief executive and chairman across several healthcare and life sciences businesses, including his current role at GENinCode.
LinkedInInvestors
